- Brasil Pharma reported a 16.5% increase in gross revenues and 10.8% same-store sales growth in 1Q13 compared to 1Q12. Adjusted EBITDA was R$34.8 million with a margin of 4.3%. - The company reinforced its regional presence by opening 9 new owned stores and adding 19 franchisees, ending the quarter with 1,115 total stores across Brazil. - Brasil Pharma completed the corporate integration of Big Ben and Guararapes, and is working to disseminate a unified culture among its over 17,000 employees.

1. 1Q13 Conference Call Presentation
May 15, 2013

2. • Gross revenues of R$814.7 million, an increase of 16.5% over 1Q12.
• Total SSS (same-store sales) of 10.8%, with 4.3% for mature stores
• Adjusted EBITDA of R$34.8 million, with adjusted EBITDA margin of 4.3%
• Adjusted net income of R$2.6 million, with adjusted net margin of 0.3%
• Reinforcement of regional presence on a country-wide scale: With the opening of 9 new owned
stores and 19 franchisees, we ended 1Q13 with a base of 1.115 stores.
• Conclusion of Big Ben & Guararapes corporate integration

3. 243 Owned stores¹
122 Owned stores
133 Owned stores
406 Franchises
211 Owned stores
Source: Brasil Pharma
709 Owned stores
406 Franchises
1,115 stores
REGIONS
Owned stores
North 118
Northeast 249
Midwest 131
Southeast
South 211
12
1
114
20
15
25
13
201
7
72
122
1
10
5 Distribution centers
93
2
National Footprint

4.  9 openings in 1Q13 (+ 8 closings)
 39.9% not yet at mature stage
1- Includes 12 stores of the Guararapes drugstore chain.
1
12.0%
17.8%
10.2%
60.1%
Stores with less than 12 months
Stores with 12 to 24 months
Stores with 24 to 36 months
Stores with more than 36 months

5. Hering Grupo Pão
de Açucar
Lojas
Americas
Magazine
Luiza
RaiaDrogasil IMC Renner BRPH Marisa
1Q12 1Q13
699.3
814.7
1Q12 1Q13
1Q12 1Q13

6. 1Q12 1Q13
Generic penetration in medicine sales
37.5% 36.5% 37.1% 38.4% 37.9%
16.4% 17.1% 17.0% 16.4% 16.5%
46.1% 46.4% 45.9% 45.2% 45.6%
1Q12 2Q12 3Q12 4Q12 1Q13
Non-medicines
Generic Medicine
Branded medicine

7.  Lower demand barred price adjustments
1Q12 1Q13
 Higher competition in some of the regions we operate

8. 1Q12 1Q13
Sales expenses SG&A total
1Q12 1Q13
G&A % Sales expenses % SG&A total %
1Q12 2012 1Q13
Proforma Proforma
Gross Revenues 699,349 3,094,293 814,653
General and administrative expenses (G&A) (51,464) (206,540) (46,501)
% Gross Revenues 7.4% 6.7% 5.7%
G&A Dilution (R$'000)

9. -50.0%
-40.0%
-30.0%
-20.0%
-10.0%
0.0%
10.0%
1Q12 1Q13
-50%
-40%
-30%
-20%
-10%
00%
10%
20%
30%
1Q12 1Q13

10. 1Q12 1Q13
Proforma
Non recurring SG&A 16,726 (5,410)
IPO /Debenture issuance expenses (108)
Stock Option Plan (SOP) (1,508) (2,816)
M&A/Branding (1,807) (684)
Income related to Santana insurance 21,653
Platforms Integration/Downsizing (1,504) (1,763)
Other (147)
Non recurring expenses (R$'000)

11. Cash position and indebtedness (R$'000) 1Q12 4Q12 1Q13
(+) Loans and financing 344,487 177,049 169,079
Short term 241,251 83,229 44,864
Long term 103,236 93,820 124,215
(+) Debentures - 253,642 258,937
Short term - 5,237 10,427
Long term - 248,405 248,510
(+) Accounts payable for investment acquisition 347,212 345,333 264,430
Short term 34,833 99,711 82,833
Long term 312,379 245,622 181,597
(=) Total Indebtedness 691,699 776,024 692,446
Short term (%) 39.9% 24.2% 19.9%
Long term (%) 60.1% 75.8% 80.1%
(-) Cash and cash equivalents (122,901) (368,751) (183,870)
(=) Net Debt 568,798 407,273 508,576
Net debt/Adjusted EBITDA (LTM) 3.4 X 2.1 X 2.7 X
Working capial 4Q11 1Q12 4Q12 1Q13
Accounts receivable 21 22 23 24
Inventories 114 86 95 106
Suppliers 62 63 58 55
Working capital in days 72 45 60 75

12. Cash flow Statement (R$'000) 1Q12 1Q13
EBT 10,226 (7,553)
(+) Depreciation and amortization 16,092 16,462
(+) Others 13,142 24,389-
Operating cash generation 39,460 33,298
(+) Change in working capital (57,533) (83,142)
(+) Change in other non current assets and liabilities (13,918) (13,781)
Cash consumption (71,451) (96,923)
Net cash generated by operating activities (31,991) (63,624)
(-) Capex from operations (19,547) (24,922)
(-) Acquisitions (286,332) (80,903)
Net Cash from investing activities (305,879) (105,825)
(+/-) Loans and financing 196,275 (15,431)
(+) Equity funding 941 -
Net Cash from financing activities 197,216 (15,431)
Change in cash and cash equivalents (140,654) (184,881)
Cash and cash equivalents - opening balance 263,555 368,751
Cash and cash equivalents - closing balance 122,901 183,870

13. • One more step into the process of cultural integration: dissemination of a unique and national
culture to our more than 17 thousand employees;
• Endorsement: the storefront of the totality of our owned stores now carries Brasil Pharma’s
endorsement;
• Our regional brands remains, but now have beside them the name of a strong Company that
Brazil already knows and trusts

14. 1
2
CSC – Back-office of Stores & Corporate
Commercial – Procurement & Logistics
PDV – Front store3
SAP – Worldwide presence
(1.000 largest companies)
 Retail 79%
 Wholesale 69%
 Pharma Industry 100%
Implementation Phases:
Phase 1 - 2013: Financing and Accounting
Phase 2 - 2014: Procurement Department – Purchase and Logistics (under analysis)

15. Jun-11
Jul-11
Aug-11
Sep-11
Oct-11
Nov-11
Dec-11
Jan-12
Feb-12
Mar-12
Apr-12
May-12
Jun-12
Jul-12
Aug-12
Oct-12
Nov-12
Dec-12
Jan-13
Feb-13
Mar-13
Brasil Pharma IBOV
Source: Bloomberg, as of March 31st, 2013.
Company’s IPO on June 24, 2011.